Skip to content

Piper Sandler PIPR Convertible securities

Convertible securities at other companies

SiTime Corporation logo
SiTime CorporationSITM
$0
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$55.78M
UiPath logo
UiPathPATH
$30M+205%
Las Vegas Sands logo
Las Vegas SandsLVS
0
Synopsys logo
SynopsysSNPS
$0
Planet Labs logo
Planet LabsPL
$0

Other financials

Income statement

See full
Revenue$474.4M+32.8%
Net income$65.2M+0.5%
EPS (diluted)$0.92+1.1%

Balance sheet

See full
Cash & equivalents$344.4M+173%
Total debt$112.2M-3.0%
Total equity$1.3B+10.6%
Total assets$2.1B+17.0%

Cash flow

See full
Operating cash flow-$291.7M-40.8%
CapEx$2.2M-80.7%
Free cash flow-$293.9M-34.6%

Valuation

See full
Market cap$5.53B+24.3%
Enterprise value$5.3B+19.3%
P/E19.6×-2.2×
P/S2.7×-0.1×

Profitability

See full
Net margin14%+0.8pp
FCF margin18%

Returns & leverage

See full
Return on equity22%+4.5pp
Debt / equity0.1×0.0×

Where this comes from

Reported directly by Piper Sandler in its filing.

Tagged under the XBRL concept pipr:FinancialInstrumentsOwnedConvertibleDebtSecuritiesatFairValue.

The official record: Piper Sandler’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Piper Sandler's convertible securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Piper Sandler's convertible securities?
Piper Sandler (PIPR) reported convertible securities of $133.98M in Q1 2026.
How has Piper Sandler's convertible securities changed year-over-year?
Piper Sandler's convertible securities increased by 1.5% year-over-year, from $132.05M to $133.98M.
What is the long-term trend for Piper Sandler's convertible securities?
Over 5 years (2020 to 2025), Piper Sandler's convertible securities has grown at a -0.8% compound annual growth rate (CAGR), from $146.09M to $140.31M.
What does convertible securities mean?
This represents the fair value of debt securities held by the firm that can be converted into equity shares of the issuer. These instruments provide the firm with both fixed-income characteristics and potential upside participation in the issuer's growth. It reflects the firm's strategic investment in hybrid securities as part of its broader asset management or proprietary trading portfolio.